1. DOP007 Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel disease. (16th January 2018) Authors: Bor, R; Klaudia, F; Miheller, P; Palatka, K; Szamosi, T; Vincze, Á; Rutka, M; Szántó, K; Bálint, A; Szepes, Z; Nagy, F; Milassin, Á; Fábián, A; Csontos, Á; Golovics, P; Lakner, L; Müllner, K; Papp, M; Salamon, Á; Sarang, K Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S034 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P352 Ustekinumab is associated with superior treatment persistence compared to vedolizumab in Crohn's disease patients who failed to anti-TNF therapy: results from a Hungarian cohort study. (21st January 2022) Authors: Bacsur, P; Resál, T; Miheller, P; Szamosi, T; Schäfer, E; Sarlós, P; Iliás, Á; Szántó, K J; Rutka, M; Bálint, A; Fábián, A; Bor, R; Zoltán, S; Matuz, M; Molnár, T; Farkas, K Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i364 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P417 Seroconversion after COVID-19 Vaccination in Inflammatory Bowel Disease Patients. (21st January 2022) Authors: Horvath, M; Csontos, Á A; Sárközi, M; Cseprekal, O; Szijártó, A; Miheller, P Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i406 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P441 Clinical efficacy, drug sustainability and results from therapeutic drug monitoring in Crohn's disease patients treated with ustekinumab – 1-year follow-up of a prospective, nationwide, multicenter cohort from Hungary. (27th May 2021) Authors: Gonczi, L; Szanto, K; Farkas, K; Molnar, T; Szamosi, T; Schafer, E; Golovics, P; Lovasz, B; Patai, A; Vincze, A; Sarlos, P; Farkas, A; Dubrovcsik, Z; Tóth G, T; Lakatos, P L; Miheller, P; Ilias, A Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S441 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P444 COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohort. (21st January 2022) Authors: Farkas, K; Matuz, M; Kata, D; Földesi, I; Resál, T; Bacsur, P; Szántó, K; Kolarovszki-Erdei, D; Rutka, M; Fábián, A; Bor, R; Szepes, Z; Sarlós, P; Miheller, P; Zacháry, A; Molnár, T Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P534 IBD-related malignancies observed in 2015–2018: 4 years' results from the prospective nationwide Hungarian registry. (25th January 2019) Authors: Milassin, A; Rutka, M; Farkas, K; Bálint, A; Bor, R; Fábián, A; Szepes, Z; Szamosi, T; Szántó, K; Miheller, P; Barta, Z; Banai, J; Kovács, Á; Salamon, Á; Lakatos, L; Lakner, L; Palatka, K; Papp, M; Schafer, E; Novák, J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P578 Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainability. (21st January 2022) Authors: Lontai, L; Gonczi, L; Balogh, F; Komlodi, N; Resal, T; Farkas, K; Molnar, T; Golovics, P; Schafer, E; Szamosi, T; Miheller, P; Ilias, A; Lakatos, P L Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i518 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P733 Novelties of COVID-19 vaccination beyond efficacy: Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients. (30th January 2023) Authors: Resál, T; Horváth, M; Bacsur, P; Szántó, K; Rutka, M; Bálint, A; Fábián, A; Bor, R; Szepes, Z; Fekete, J; Miheller, P; Molnár, T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i862 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P797 Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with Inflammatory Bowel Disease: Results of a multicenter survey. (30th January 2023) Authors: Bikar, A; Farkas, N; Resál, T; Szepes, Z; Klaudia, F; Vincze, Á; Miheller, P; Molnár, T; Sarlós, P Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗